Long Term Outcomes of Venous Thromboembolism
Long Term Outcomes of Venous Thromboembolism
This prospective observational follow-up study is designed to assess the long-term outcomes
 after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant
 (NOAC) rivaroxaban on the prevalence of post-thrombotic syndrome (PTS).

 The study will not be testing any formal hypothesis.
This prospective observational follow-up study is designed to assess the long-term outcomes
 after VTE and to assess the effect of NOAC (rivaroxaban) on the prevalence of PTS. All
 patients diagnosed and treated for VTE at SØF from 01.01.2011 will be invited to participate
 in this study. Newly diagnosed patients will be recruited and followed-up according to the
 study schedule which is based on state of the art international guidelines.

 First follow-up will be performed at the end of treatment period, which is usually 3 or 6
 months after an event of VTE, or at one year if patients will be put on permanent AC.
 Thereafter, patients will be followed-up annually for at least 5 years or up to the end of
 the study, i.e for 10 years.

 The primary endpoints of the study are the development of PTS and CTEPH after VTE. There will
 be 3 visits: at 3 or 6 months depending on the duration of AC, at 2 and 5 years, in addition
 to a visit for TTE at 6 months. Remaining follow-ups will be performed by phone or by mail.
 All patients with PE will be examined by TTE 6 months after the diagnosis of PE. Those with
 signs of PAH will be referred for further work-up to establish the presence or absence of
 CTEPH at specialized centres. Patients with DVT will be evaluated for PTS at 2 and 5 years
 and for CTEPH if they develop dyspnoea. As for part b of the primary objective, the study
 will allow inclusion of patients with previous DVT diagnosed after 01.01.11.
Inclusion Criteria:

 -  Patients with objectively verified first time DVT diagnosed after 01.01.11 for study
 A, OR objectively verified DVT and/or PE dignosed after 01.04.14 for study B.

 -  18 years of age

 -  Signed informed written consent

 Exclusion Criteria:

 -  Patients who refuse to consent

 -  Patients who have been treated with other anticoagulants than thoose included in the
 study

 -  Patients who can not participate due to logistic reasons